- Title: Persistently high TB prevalence in Nairobi County neighbourhoods, 2015-2022
- 2 Jane R. Ong'ang'o^{1*}, Jennifer Ross², Richard Kiplimo³, Cheryl Kerama¹, Khai Hoan Tram², Jerry S. Zifodya⁴, Nellie
- 3 Mukiri⁵, Erick Nyadimo¹, Martha Njoroge¹, Aiban Ronoh⁶, Immaculate Kathure⁶, Dickson Kirathe⁶, Thomas R.
- 4 Hawn^{2,7}, Videlis Nduba¹, David J. Horne^{2,7}
- 5

1

- ⁶ ¹Centre for Respiratory Diseases Research, Kenya Medical Research Institute, Nairobi, Kenya
- 7 ² Department of Medicine, University of Washington, Seattle, WA, USA
- 8 ³ Amref Health Africa, Nairobi Kenya
- 9 ⁴ Section of Pulmonary, Critical Care & Environmental Medicine, Tulane University, New Orleans, LA, USA
- 10 ⁵ National TB Reference Laboratory, Ministry of Health, Kenya
- ⁶ National TB, Leprosy and Lung Disease Programme, Ministry of Health, Kenya
- 12 ⁷ Department of Global Health, University of Washington, Seattle, WA, USA
- 13
- 14 *Corresponding author: <u>irnabongo@gmail.com</u> (JRO)
- 15
- 16

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

17 Abstract

18 National and sub-national population-based surveys, when performed at intervals, may assess important changes in 19 TB prevalence. In 2022 we re-surveyed nine Nairobi County neighbourhoods that were previously surveyed in 2015. 20 We aimed to determine pulmonary TB prevalence, compare prevalence to 2015 estimates, and evaluate changes in risk groups. Participants who reported cough of any duration and/or whose chest x-ray suggested TB submitted 21 sputum for smear microscopy, Xpert Ultra, and liquid culture. We defined prevalent TB as Mycobacterium tuberculosis 22 23 detection by sputum Xpert or culture, excepting individuals who were only trace positive. Our methods differed from 2015, which used solid media, Xpert MTB/RIF, and cough duration >2 weeks. We calculated TB prevalence using 24 25 random-effects logistic regression models with missing value imputations and inverse probability weighting. In 2022 26 among 6369 participants, 1582 submitted >1 sputum sample, among whom 42 (2.7%) had TB, a weighted TB 27 prevalence of 806/100,000 (95% confidence interval (CI), 518-1096). An additional 31 (2.0%) participants tested Ultra 28 trace-positive/culture-negative. For comparison to 2015, we excluded 2022 participants (n=2) whose only criterion for 29 sputum was cough <2 weeks. There was no evidence for a decline in overall TB prevalence from 2015 to 2022. TB 30 prevalence among men was high (1368/100,000) but unchanged compared to 2015 (p-value = 0.50). The age group with the highest estimated prevalence remained people ages 45-54 years. Among people with prevalent TB who 31 32 reported cough, 76% had not sought health care. Dissimilar from other serial surveys that showed declines in TB 33 prevalence, we found persistently high TB prevalence over a 7-year period in Nairobi County. Limitations of this study 34 include changes in methodology between the two surveys and complex effects of the COVID-19 pandemic.

35 Key words: TB prevalence, Nairobi county neighbourhoods, Xpert Ultra

- 37
- 38
- 39

40 Introduction

An estimated 10.6 million people fell ill with tuberculosis (TB) globally in 2022, an increase compared to 10.3 million in 2021 [1]. The number of people officially reported with TB in 2022 was 7.5 million, the highest number since global TB monitoring started in 1995. The global gap between estimated and reported number of people with TB, 3.1 million in 2022, contributes disproportionately to TB deaths, TB transmission, and perpetuates challenges in developing TB control policies [2]. There is an urgent need for strategies to increase the proportion of people with TB who are diagnosed and to decrease the time to diagnosis.

47

Kenya is categorized as one of 30 high TB burden countries globally, with an estimated 128,000 people who developed TB in 2022 [1], among whom more than 40% were not reported to the national TB program. In 2015-16, Kenya conducted a nationwide TB prevalence survey, the first since 1958 [3, 4]. Through this effort, there was an upward revision of the national TB prevalence rate to 348 per 100,000 population, compared to a pre-survey estimate of 233/100,000 [3]. Additional findings were that only 46% of Kenyans with TB were diagnosed and started on treatment, with the largest gaps among people 25-34 years and those over 65, and that 65% of people with symptomatic TB had not sought health care prior to the survey.

55

Population-based TB prevalence surveys offer the most accurate estimates of TB burden [5]. National and subnational surveys, when performed at short intervals, may assess trends in TB prevalence, evaluate the impact of public health interventions, identify characteristics associated with differences in TB prevalence and inform public health responses. Although several Asian countries [6-9] have recently performed serial national or sub-national TB prevalence surveys using WHO protocols, to our knowledge, this has not occurred in any country on the African continent [10].

62

Nairobi County, home to Kenya's capital city, reported 10,598 patients diagnosed with drug-susceptible TB in
2021 (13.6% of all Kenyan TB notifications), the highest number of any Kenyan county [11]. We performed a
limited prevalence survey by re-visiting nine of the ten geographic clusters in Nairobi County that were previously

- surveyed in the 2015-16 Kenya national prevalence survey. We aimed to determine the prevalence of
 bacteriologically-confirmed pulmonary tuberculosis in those 15 years and older, evaluate temporal trends in TB
 prevalence over a 7-year period (2015 to 2022), and characterize the health care seeking behavior of persons
 with TB. We hypothesized that TB prevalence decreased between 2015 and 2022 in the setting of the prior survey,
 the COVID-19 pandemic, and declines in estimated TB incidence nationally in Kenya [1].
- 71

72 Methods and materials

73 Survey design and target population

We performed a cluster-based cross-sectional survey, enrolling participants between May and December 2022 using the WHO recommended protocol [5]. Each cluster was defined using the same geographical borders as the 2015-16 prevalence survey (Fig. 1) [4]. Due to funding, we surveyed nine of 10 clusters included in the 2015-16 survey. Individuals were eligible for enrollment if they were aged 15 years and above, had resided in the surveyed household for at least 30 days prior to the survey date, and provided informed consent.







Target Enrollment 81

- 82 Based on the methods used in the 2015-16 survey [4], a sample size of 6,480 adults was targeted in the nine
- clusters with an estimated average of 720 adults enrolled from each cluster (allowable cluster range 650-790). 83
- 84 All the clusters were urban.
- 85
- **Survey Field Procedures** 86
- 87 Pre-survey procedures
- Prior to deploying the survey field teams, engagement visits were made to appropriate officials at the county and 88
- 89 cluster levels to sensitize local authorities on the survey and to obtain their support for survey interventions.
- Mapping of cluster borders (based on those used in the 2015-16 survey) occurred in this pre-survey phase. 90
- 91

Survey field procedure at households 92

Study clusters were surveyed one at a time using two field-based teams, a mobilization team and an active survey 93 94 team. The former engaged in community sensitization and mobilization while the latter conducted the survey. In 95 each cluster, the mobilization team performed a door-to-door census using a listing questionnaire to identify 96 eligible residents aged 15 years and above until reaching 650–790 persons. The listing questionnaire collected 97 demographic data on household members regardless of age. A household socioeconomic questionnaire was then 98 administered to each household head. The household-level survey procedures were similar for both surveys. A 99 central team based at the Center for Respiratory Diseases Research at the Kenyan Medical Research Institute (CRDR-KEMRI) provided coordination, monitoring, data management and analysis, and case management. 100

101

Mobile field site procedures 102

Eligible participants were invited to the mobile field site where questionnaires, including a symptom screen, and 103 104 digital chest X-ray (posteroanterior) were performed. Chest X-ray images were independently evaluated on-site by two trained clinical officers using standardized WHO criteria as either "normal", "abnormal suggestive of TB", 105 or "abnormal other". Study participants who reported a cough of any duration (positive symptom screen) and/or 106 had an abnormal chest X-ray suggestive of TB were eligible for sputum collection. In the 2015-16 survey only 107

participants who reported a cough duration of 2 or more weeks were considered positive on their symptom screen; in the present study we chose a cough of any duration to maximize sensitivity based on the accuracy of cough as a symptom screen for TB [12] while also collecting data on cough duration to allow comparisons between the two surveys. Like the 2015-16 survey, we collected sputum from participants who declined to undergo chest radiographs. Individuals with no radiological abnormalities suggestive of TB and who denied cough did not submit sputum samples.

114

115 Laboratory Procedures

Similar to the 2015-16 survey, we collected two sputum samples from sputum-eligible participants: a "spot" 116 sputum collected at the time of the initial mobile field site visit and a morning sputum, collected by the participant 117 118 at home on the following morning. These specimens were transported daily under cold chain for processing to 119 CRDR-KEMRI and/or the National Tuberculosis Reference Laboratory (NTRL), both located in Nairobi. Laboratory processes were performed at the CRDR, NTRL, or the CDC/KEMRI lab in Kisian, Kenya. We performed direct 120 121 sputum smears on all samples using Auramine O followed by fluorescence smear microscopy. GeneXpert 122 MTB/RIF Ultra (Xpert Ultra, Cepheid, Sunnvvale, CA, USA) was performed on morning sputum samples or on spot 123 samples when a morning sample was not available. Xpert Ultra results were recorded as cycle threshold (Ct) values for all probes and as a semi-quantitative grade (Negative, Trace, Very Low, Low, Medium, High). The lowest 124 125 Ct value from any of the four rpoB probes was assigned as the minimum Ct value. For participants with Ultra trace positive results, which are generally positive only for the insertion sequence (IS) probe, we assigned a minimum 126 Ct value of 35 which is near the upper limit of detection. Both spot and morning sputum specimens underwent 127 128 AFB-culture with Mycobacteria Growth Indicator Tube (MGIT 960, Becton Dickinson, Franklin Lakes, NJ, USA using 7ml tubes supplemented with BD BBL[™] MGIT[™] OADC and BD BBL[™] MGIT[™] PANTA, and were incubated in an 129 130 automated BACTEC MGIT 960 machine for growth determination. Samples that had zero growth units at 42 days were confirmed negative. Broth cultures that were flagged as positive by the MGIT 960 were subjected to brain 131 132 heart infusion (BHI) agar for sterility and Ziehl-Nielsen staining for the presence of Acid-Fast Bacilli (AFB). Once AFB presence was confirmed, the broth was then subjected to immunochromatographic assay (BD MGIT[™] TBc 133

ID, Capillia test) for confirmation of *Mycobacterium tuberculosis* complex (MTBC). For isolates confirmed as
 MTBC, drug susceptibility testing was done using BD BBL[™] MGIT[™] SIRE kit and positive isolates were aliquoted
 for future reference.

137

Our use of Xpert Ultra differed from the 2015-16 prevalence survey, which used Xpert MTB/RIF, an earlier generation of the assay. To inform comparisons with the earlier survey, we conducted side-by-side testing of Xpert Ultra versus Xpert MTB/RIF in 40 samples selected randomly within semi-quantitative grade strata of Xpert Ultra results. Additionally, culture media differed between surveys as the 2015-16 survey used Lowenstein-Jensen (LJ) solid medium culture while we used MGIT liquid culture in 2022; the latter is a more sensitive culture medium [13].

144

145 Survey TB case definition

We defined a participant as having prevalent pulmonary TB if the Xpert Ultra result was positive at a semi-146 quantitative grader higher than trace positive and/or at least one sputum culture was positive for *M. tuberculosis*. 147 Different from Kenya Ministry of Health policies, we considered specimens that were Xpert Ultra trace positive 148 and culture negative as negative for TB (i.e., false positive result). We based this definition on uncertainty around 149 the interpretation of Xpert Ultra trace positive results which may be due to prior TB disease, transient infection, 150 or true positive results among other causes [14-17]. The 2015-16 survey performed PCR-testing using the Xpert 151 MTB/RIF assay, which does not have a trace positive grade, and defined pulmonary TB as any GeneXpert MTB/RIF 152 positive result and/or one or more sputa cultures positive for *M. tuberculosis*. A sub-group of trace-positive 153 participants were enrolled into a study of TB infectiousness [18] and had two additional sputa collected for MGIT 154 culture, one of which underwent Xpert Ultra testing; we report these results. All participants diagnosed with 155 culture-positive TB or with a positive Xpert Ultra test (including trace positive results) were linked to local health 156 facilities for treatment initiation by the survey field coordinator and community health volunteers. The County 157 TB coordinator was informed of all confirmed TB diagnoses and a documented laboratory result form with this 158 information was delivered to the treatment health facility. 159

160

Data Collection and management 161

We collected data in the field using REDCap [19], a web-based application installed on tablet devices. HIV status 162 and diabetes were based on self-report. 163

164

Data Analysis 165

The primary outcome was the prevalence of bacteriologically confirmed pulmonary TB expressed per 100,000 166 population. Secondary outcome measures were pulmonary TB prevalence by age groups and sex, description of 167 symptoms and radiological findings for pulmonary TB, and the health seeking behaviors of individuals with 168 symptomatic pulmonary TB. Descriptive analyses were done using R software version 4.3.1. All tests were two 169 sided and p-values <0.05 were considered significant. The random-effect logistic regression model recommended 170 by the WHO [20] and adopted in the Kenya National TB Prevalence Survey [4] was applied. This model uses robust 171 172 standard errors with missing value imputations and inverse probability weighting to correct for differentials in participation in the survey by age, sex, and cluster. This model accounts for clustering and variation in the number 173 174 of individuals per cluster when estimating the point prevalence of pulmonary TB and 95% confidence intervals (CIs)[3]. We used Stata version 15 (StataCorp, College Station, TX) using the mim and svy commands with 175 176 pweights specified to adjust for design effect. We analyzed data from the 2015 and 2022 prevalence surveys using the same code to generate prevalence estimates. A sensitivity analysis of individuals from the 2022 survey 177 using a cough definition of at least two weeks was performed. To compare case notification rates with prevalence 178 estimates, we calculated case notification rates (CNRs) for each age group from the routine TB data notified to 179 National TB program. These were plotted alongside the prevalence estimates, including the confidence intervals. 180

181

Ethical Considerations 182

This study was approved by the Institutional Review Boards of KEMRI (KEMRI/SERU/3988) and the University of 183 Washington (UW STUDY00009209). The risks and benefits of the study were explained to participants, and each 184

- signed a written informed consent. For eligible participants below 18 years of age, we obtained guardian consent
- 186 and participant assent.
- 187

188 Results

189 Enrollment

- From May to December 2022, we conducted a household census in nine Nairobi geographic clusters. We identified 9,459 residents among whom 1,799 were less than 15 years of age (Fig 2). Out of 7,644 persons eligible for enrollment, 83% (n=6,369) enrolled. This enrollment proportion was lower than the 2015-16 survey, which had 89% (6,834/7,631) enrollment. Supplementary Table 1 shows the demographic characteristics for people who enrolled and did not enroll in the 2022 survey. The participation rate among men and women was 77% and 89%, respectively. The participation pattern across the age groups was similar for both men and women (S1 Fig).
- 196
- 197 The median age of study participants in 2022 was 33 years (IQR 24-42) compared to 30 years (IQR 24-39) in 2015.
- 198 Age groups skewed to older ages in 2022 compared to 2015 (p-value <0.001). (Table 1) Among enrollees in 2022, the
- 199 proportion of women (66%) was greater than men (34%). While the proportion of women (59%) was also greater than
- 200 men (41%) in the 2015-16 survey, women represented a significantly greater proportion in 2022 (p<0.001). Median
- household size and the number of participants living alone were 2 (IQR 2-4) and 23.9% in 2022, respectively. There
- 202 were differences in occupations, marital status and education levels between the two surveys including an increase in
- reported unemployment from 14% of participants in 2015 to 21% in 2022.
- 204
- 205
- 206





Fig 2. Schematic diagram of participant enrollment and screening in the 2022 prevalence survey 208

209

Table 1. Social and demographic characteristics of Nairobi prevalence survey participants in 2015 and 210 2022. 211

Characteristic	2015 , N = 6,132 ¹	2022 , N = 6,369 ¹	p- value ²
Age group			<0.001
15 -24	1,694 (28%)	1,662 (26%)	
25 - 34	2,134 (35%)	1,902 (30%)	
35 - 44	1,199 (20%)	1,450 (23%)	
45 - 54	642 (10%)	751 (12%)	
55 - 64	287 (4.7%)	392 (6%)	
65+	176 (2.9%)	212 (3%)	
Age	30 (24 – 39)	33 (24 – 42)	
Sex			<0.001
Female	3,622 (59%)	4,182 (66%)	
Male	2,510 (41%)	2,187 (34%)	
Diabetes		328 (5%)	
PLHIV			0.10
Positive	186 (3%)	137 (2·2%)	
Negative	4,295 (63%)	4,014 (63%)	
Did not disclose	2,353 (34%)	2,218 (35%)	
Number of household members		2 (2 – 4)	
Participant lives alone (%)		1521 (24%)	
Occupation			<0.001
Self-employed	2,903 (47%)	2774 (44%)	
Employed by government	170 (2.8%)	84 (1%)	
Employed in private sector	886 (14%)	613 (10%)	
Pupil/student	543 (8.9%)	586 (9%)	
Housewife	646 (11%)	880 (14%)	
Unemployed	873 (14%)	1,309 (21%)	
Other	111 (1.8%)	120 (2%)	
Unknown	0	3	
Marital Status			<0.001
Single (Never been married)	1,868 (30%)	2,134 (34%)	
Married	3,796 (62%)	3,817 (60%)	
Divorced/separated	307 (5.0%)	262 (4%)	
Missing	161 (2.6%)	155 (2%)	
	U	T	<0.001
No Schooling	145 (2 4%)	166 (3%)	10 001
Primary School. Not Completed	1.041 (17%)	723 (11%)	
	.,	(,0)	

			μ-
Characteristic	2015 , N = 6,132 ¹	2022 , N = 6,369 ¹	value ²
Completed Primary School	1,480 (24%)	1,223 (19%)	
Secondary School, Not Completed	937 (15%)	1,266 (20%)	
Completed Secondary School	1,635 (27%)	2,280 (36%)	
Further education after Secondary School	894 (15%)	710 (11%)	
Missing	0	1	

212 ¹ Median (IQR) or Frequency (%)

213 ² Pearson's Chi-squared test

214

We found that 63% of 2022 survey participants lived in the same location in 2015 (S2 Table). An additional 8% reported living in the same cluster as in 2015-2016 but had moved households. Thirteen percent of participants reported participating in the prior survey. Across clusters, migration was noted to be highest in cluster 2 with 79% of the participants indicating that they did not live in the same household in 2015. The nine surveyed clusters differed in several characteristics including sex distribution and the frequency of participants using tobacco and consuming

220 alcohol. (S3 Table)

221

222 Survey screening results

Based on a cough of any duration and/or abnormal chest X-ray consistent with TB, 2,043 participants were screen 223 224 positive (32.1% of 6369 persons screened) and eligible to submit sputum samples in the 2022 survey. Among these 225 participants, 1.018 (49.8%) were eligible by chest X-ray alone, 634 (31.0%) eligible based on the presence of a cough, 226 and 387 (18.9%) eligible by both screening methods. An additional 4 study participants who did not receive a chest Xray and did not have cough symptoms were eligible for sputum collection (Fig 1). Cough of any duration was reported 227 by 1,021/6,369 (16%) participants and was the most frequently reported symptom, followed by chest pain (9.8%), and 228 229 cough > 2 weeks (5.7%) (Table 2). Cough of any duration, fever, and chest pain were less frequent in the 2022 prevalence survey compared to 2015. The presence of cough of any duration was similar (p-value 0.07) for men (15%) 230 and women (17%). Cough frequency was higher (p<0.001) among older age groups (22% for 45-54 years, 23% for 55-231 64 years, 25% for \geq 65 years) than younger age groups (14% for 15-24 years, 13% 25-34 years, 16% for 35-44 years). 232

233

Table 2. Comparison of symptoms characteristics of the study participants between 2015 and 2022 surveys

Characteristic	2015 , N = 6132 ¹	2022 , N = 6,369 ¹	p-value ²
Cough of any duration	1,018 (17%)	1,021 (16%)	0.005
Cough (>2weeks)	292 (4.8%)	366 (6%)	0.20
Missing	0	1	
Chest pain	782 (13%)	625 (10%)	<0.001
Fever	112 (1.8%)	99 (2%)	0.03

Night sweats	160 (2.6%)	140 (2%)	0.09
Weight loss	31 (0.5%)	93 (2%)	<0.001
Shortness of breath	406 (6.6%)	239 (4%)	<0.001
Number of symptoms present			<0.001
No symptoms	4,501 (73%)	4,958 (78%)	
Only 1 symptom	979 (16%)	839 (13%)	
Only 2 symptoms	403 (6.6%)	330 (5%)	
3 or more symptoms	249 (4.1%)	242 (4%)	

235 ¹ Median (IQR) or Frequency (%)

236 ² Pearson's Chi-squared test

237

TB Prevalence in 2022

Of the 2,043 participants eligible to submit sputum, 1,582 (77.4%) submitted at least one sputum sample. There were 239 42 (2.7%) persons who met the study definition of TB, among whom 27 were culture and Xpert Ultra positive, 5 were 240 culture-positive only, and 10 were Xpert Ultra positive only (Fig 2). Twenty-seven of the participants with pulmonary 241 TB had smear-positive sputum. There were 31 participants who were Xpert Ultra trace positive and culture-negative, 242 243 representing 2.0% of all participants who submitted sputum; these persons did not meet the study definition of pulmonary TB. There was one participant who was taking TB treatment at the time of the survey. For comparison to 244 245 2015, we conducted an analysis of the 2022 data based on "restricted eligibility" that excluded participants whose only eligibility criterion to submit sputum was cough <2 weeks, resulting in a decrease of 3 persons with TB (n=39). 246

247

In the nine clusters in 2022, the crude TB prevalence was 659/100,000 (95% CI, 487/100,000 – 892/100,000) and the crude prevalence of smear-positive pulmonary TB was 294/100,000 (95% CI, 185/100,000 – 466/100,000). Crude prevalence point estimates were higher in seven of the nine clusters in 2022 relative to 2015 (S4 Table), although these differences were not significant. When the symptom screen was limited to cough ≥2 weeks, 2022 crude TB prevalence was 612/100,000 (95% CI, 447/100,000 – 838/100,000) which, compared to the 2015 crude prevalence of 538/100,000 (95% CI, 383/100,000 – 756/100,000), was a non-significant increase in the point estimate of 14%.

254

In 2022, the weighted prevalence of TB was 806/100,000 (95% CI, 518/100,000 – 1096/100,000) (Table 3). There were
27 and 37 participants with smear-positive and Xpert Ultra positive TB in the 2022 survey, respectively. The estimated

weighted prevalence of smear-positive TB was 583/100,000 (95% Cl, 301-866/100,000) and of Xpert Ultra positive TB
was 602/100,000 (95% Cl, 350-854/100,000). The weighted prevalence of all TB was higher (p-value = 0.03) among
men (1394/100,000, 95% Cl 802/100,000 – 1985/100,000) than among women (455/100,000, 95% Cl 179/100,000 –
730/100,000). Similar to findings from 2015 in the nine clusters, the age group weighted TB prevalence was highest
for persons 45-54 years of age (Table 3) who had had the largest difference between estimated prevalence and case
notification rates (Fig 3).



263

Fig 3. Comparison of Nairobi TB case notification rate 2022 and estimated TB prevalence in 2022 by age group

The weighted TB prevalence in 2022 based on restricted eligibility was 761/100,000 (95% CI 450/100,000 -1,073/100,000), compared to 567/100,000 (95% CI, 267/100,000-866/100,000) in 2015 (p=0·41). In stratified analyses, the point estimates of TB prevalence among men and among women were each 43% higher in 2022 than in 2015, though these differences did not achieve statistical significance (Table 3, Fig 4). Similarly, the point estimates of TB prevalence in each age group were higher in 2022 than in 2015.

- 271
- 272
- 273
- 274
- _/ .
- 275
- 276

277 Table 3. Estimated weighted pulmonary TB prevalence in 2022 survey by cough duration and in 2015 survey

	2022: cough any duration	2015: cough >2 weeks	2022: cough >2 weeks	
Robust standard errors with multiple imputation and inverse probability weighting	Bacteriologically Confirmed (N=42) Point estimate (95%CI)	Bacteriologically confirmed (N=33) Point estimate (95%Cl)	Bacteriological Confirmed (N=39) Point estimate (95%CI)	P-value comparing 2022 restricted analysis to 2015
Overall 1	806 (518, 1,096)	567 (267, 866)	761 (450, 1,073)	0.41
Smear-positive TB 3	583 (301, 866)	316 (116, 517)	557 (303, 811)	0.17
GeneXpert positive TB 3	602 (350, 854)	491 (234, 747)	556 (309, 804)	0.70
Sex 2				
Women	455 (179, 730)	306 (107, 505)	439 (215, 664)	0.34
Men	1394 (802, 1,985)	908 (388, 1,429)	1301 (734, 1,868)	<0.001
Age 3				
15-24 years	407 (117, 697)	339 (142, 436)	449 (126, 773)	0.43
25-34 years	853 (251, 1,456)	597 (174, 1,021)	791 (311, 1,272)	0.18
35-44 years	875 (335, 1,414)	615 (229, 1,003)	814 (204, 1,425)	<0.001
45-54 years	1,375 (361, 2,390)	880 (75, 1,685)	1,164 (452, 1,875)	<0.001
55-64 years	1,115 (209, 2,021)	832 (127, 1,537)	1,102 (129, 2,074)	0.44
65 years and older	479 (0, 1,433)	437 (0, 1,443)	579 (0, 1,609)	0.27

Variables included in this model: Cough of any duration, night sweats, age group, sex, chest X-ray field reading, weight loss

- 278
- 279



281

Fig 4. Weighted TB prevalence by sex in 2015 and 2022 surveys. 282

283

Participants with TB: characteristics, symptoms, CXR 284

Forty-two participants met the survey definition of TB, including 27 (63%) men, 4 (11%) persons living with HIV, and 1 285 (2.3%) with diabetes. In addition, 5 (12%) participants reported current smoking while 13 (29.4%) reported alcohol use 286 (Table 4). Among participants with prevalent TB, 64% (n=27) denied cough of two or more weeks and 40% (n=17) 287 288 denied cough of any duration (Table 4). Among participants with TB and cough, the median cough duration was 2 weeks (IQR: 1-3). The WHO recommends a four symptom screen for pulmonary tuberculosis that is based on the 289 presence of one or more of cough, fever, night sweats, or weight loss. Using the WHO screen, 62% (n = 26) of 290 291 participants with TB would have screened positive.

292

Participants with Xpert Ultra trace positive results 293

294 Notably, 31 participants had sputum that was Xpert Ultra trace positive and culture-negative; this represents 2.0% of participants who submitted sputum. There were no samples that were trace positive and culture-positive based on 295 296 the prevalence survey protocol (Table 4). Among Xpert Ultra positive/culture-negative participants, cough of any duration was the most common symptom and present in 21/31 (62%), which was similar in frequency to participants 297 who were diagnosed with prevalent TB, among whom 25/42 (58%) reported cough (Table 4). Aside from coughing, the 298

299 second most common symptom reported by the 2 groups was chest pain. A prior history of TB was reported by 7% (2/31) of participants with trace positive/culture-negative sputum. Seventeen of the 31 trace-positive/culture-300 negative participants were referred to a study in which they had two additional sputa collected for liquid-media based 301 302 culture. Of these 17 participants, all re-tested as Xpert Ultra trace positive and four were culture positive on one of the additional sputum samples (24%). 303

304

305 Table 4. Characteristics of participants with prevalent TB or Xpert Ultra Trace results

Characteristic	Culture-positive, Ultra negative	Culture- positive, Ultra Positive	Culture-negative, Ultra Trace	Overall , N = 73	p- value
	N = 5	N = 37	positive, N = 31		
Sex					0.3
Male	2 (40%)	25 (68%)	17 (55%)	44 (60%)	
Female	3 (60%)	12 (32%)	14 (45%)	29 (40%)	
Age group					>0·9
15 -24	1 (20%)	4 (11%)	5 (16%)	10 (14%)	
25 - 34	2 (40%)	11 (30%)	9 (29%)	22 (30%)	
35 - 44	2 (40%)	9 (24%)	8 (26%)	19 (26%)	
45 - 54	0 (0%)	8 (22%)	5 (16%)	13 (18%)	
55 - 64	0 (0%)	4 (11%)	3 (9.7%)	7 (9.6%)	
65+	0 (0%)	1 (2.7%)	1 (3.2%)	2 (2.7%)	
HIV status					0.9
Negative	4 (100%)	17 (85%)	15 (79%)	36 (84%)	
Positive	0 (0%)	3 (15%)	4 (21%)	7 (16%)	
Unknown	1	17	12	30	
Diabetes	4 (80%)	36 (97%)	29 (94%)	69 (95%)	0.2
Prior Hx of TB	0	1 (3%)	2 (7%)	3 (4%)	>0.9
Smoking					0.3
Never	5 (100%)	32 (86%)	28 (90%)	65 (89%)	
Current smoker	0 (0%)	5 (14%)	1 (3.2%)	6 (8.2%)	
Former smoker	0 (0%)	0 (0%)	2 (6.5%)	2 (2.7%)	
Alcohol					0.02
Never	3 (60%)	26 (70%)	31 (100%)	60 (82%)	
Once a month or less	0 (0%)	2 (5.4%)	0 (0%)	2 (2.7%)	
2 to 4 times a month	1 (20%)	2 (5.4%)	0 (0%)	3 (4.1%)	
2 to 3 times a week	1 (20%)	5 (14%)	0 (0%)	6 (8.2%)	
4 or more times a week	0 (0%)	2 (5.4%)	0 (0%)	2 (2.7%)	

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.					
Reported symptoms					
Cough of any duration	4 (80%)	21 (57%)	21 (68%)	46 (63%)	0.6
Cough > 2wks	1 (20%)	14 (39%)	8 (29%)	23 (33%)	0.6
Unknown	0	1	3	4	
Fever	0 (0%)	4 (11%)	2 (6.5%)	6 (8.2%)	0.8
Weight loss	1 (20%)	4 (11%)	1 (3.2%)	6 (8.2%)	0.2
Night sweats	1 (20%)	6 (16%)	2 (6.5%)	9 (12%)	0.3
Fatigue	2 (40%)	8 (22%)	5 (16%)	15 (21%)	0.4
Shortness of breath	0 (0%)	6 (16%)	7 (23%)	13 (18%)	0.6
Chest pain	3 (60%)	12 (32%)	13 (42%)	28 (38%)	0.4
One or more of WHO	4 (80%)	22 (59%)	21 (68%)	47 (64%)	0.6
screening symptoms					
(cough/fever/weight					
V ray findings					0.007
	- (()	- (()			0.007
Normal	2 (40%)	2 (5.6%)	10 (33%)	14 (20%)	
Abnormal, suggestive of TB	3 (60%)	34 (94%)	20 (67%)	57 (80%)	
Unknown	0	1	1	2	

medRxiv preprint doi: https://doi.org/10.1101/2024.09.30.24314683; this version posted October 1, 2024. The copyright holder for this

306 ¹ Median (IQR) or Frequency (%)

307 Laboratory/Microbiologic Results

Rifampicin resistance was not detected by Xpert Ultra or phenotypic drug susceptibility testing (DST). DST identified 2 participants with isolates resistant to streptomycin and isoniazid and one isolate resistant to ethambutol. Among the 68 participants with Xpert Ultra results that were trace positive or higher, 31 (46%) were trace positive, 8 (12%) very low, 14 (21%) low, 6 (9%) medium, and 9 (13%) high semi-quantitative grade. An increasing percentage of samples were culture positive with increasing Xpert Ultra grade; those with "very low" positivity had 25% culture positivity as compared to 100% culture positivity in those with "high" positivity on Xpert Ultra (S5 Table).

314

315 Xpert Ultra compared to GeneXpert MTB/RIF

In comparative analyses of Xpert Ultra and GeneXpert MTB/RIF, 40 samples were selected. Of the 13 samples that were trace positive by Xpert Ultra testing, only 1 was positive on GeneXpert MTB/RIF (S6 Table). Fourteen (82%) of the 17 Xpert Ultra participants with positive results > trace were also test positive by GeneXpert MTB/RIF; thus, Xpert Ultra detected 3 additional persons with tuberculosis. Two of these participants had semi-quantitative grades of very low on Xpert Ultra, and one was low. All the negative Xpert Ultra participants were also negative on GeneXpert MTB/RIF with valid results. On further comparison of Xpert Ultra and GeneXpert MTB/RIF classification of positivity by cycle threshold, GeneXpert classes correlated well.

Discussion 324

In a population-based study of pulmonary TB prevalence in nine geographic clusters in Nairobi County, Kenya, we 325 found that the estimated prevalence of TB remained high from 2015 to 2022. Despite programmatic interventions 326 after the 2015 survey, there was no evidence of a decline in TB overall, by sex, or in age subgroups, a finding that 327 328 differs from other serial surveys in high TB burden settings during similar time periods. We also found that men and 45-54 year old participants belonged to groups with higher risk for TB in these geographic clusters in both 329 2015 and 2022. This suggests that in Nairobi County, local drivers of the TB epidemic are stable and may be used 330 to develop targeted TB control interventions. Without specific interventions, it is likely that TB burden will remain 331 332 high.

333

After 2015 TB prevalence survey results revealed that 40% of people with prevalent TB had not been previously 334 diagnosed [3], Kenya initiated public health interventions that are on-going to close the gap in TB case detection. 335 This included greater access at government clinics to GeneXpert and other WHO recommomended rapid diagnostic 336 tests as first-line TB diagnostics, increased use of digital X-ray for screening with CAD interpretation, strengthened 337 processes for community referrals of persons presumed to have TB to government clinics, more efficient contact 338 investigations, and programmatic support for quality improvement at the health facility level. While there were 339 challenges in implementing these initiatives, such as erratic availability of Xpert cartridges, the estimated frequency 340 of undetected TB reduced to 32% in 2022 [21]. Concerningly, we found that the prevalence of TB in re-sampled 341 Nairobi clusters remained unchanged from 2015 to 2022, with higher point estimates overall and in seven of 342 nine sampled clusters; in addition, only one participant with TB was on treatment at the time of our survey. 343

344

In comparing our results from 2022 and 2015, it is important to note that the TB detection methods used in 345 2022 were more sensitive than those used in 2015. Liquid broth-based culture is estimated to be approximately 346 347 16% more sensitive than culture on solid media [13], and a meta-analysis of studies that directly compared GeneXpert assays found that, compared to culture, the sensitivity of Xpert Ultra and Xpert MTB/RIF were 90.9% 348 and 84.7%, respectively, a difference of 6.3% [16]. In a limited head-to-head comparison, we also found that 349 Xpert Ultra detected more people with TB than Xpert MTB/RIF. Beyond differences in testing, additional factors 350 likely contributed to the persistently high TB burden in 2022. There were health services disruptions in the two 351 years immediately preceding the 2022 survey, including a COVID-19 related decrease in TB case notifications 352 and a Kenyan healthcare worker strike in December 2020 – January 2021 [22]. While TB case notifications 353 subsequently increased [1], disruptions in TB diagnosis and treatment associated with these events likely 354 contributed to the persistently high TB prevalence observed in 2022. Similar COVID-19 related disruptions on 355 public health services and their impact on TB control were observed globally in diverse settings including TB 356 357 endemic and non-endemic nations. We also observed a significant increase in participants who were

unemployed in 2022 compared to 2015, which may predispose to economic deprivation and higher TB risk. In
 other settings, economic growth has been associated with declines in TB prevalence between sequential
 surveys [23]. This change in employment may have been due to COVID-19-related effects.

361

The lack of decline in TB prevalence over a seven-year span differs from other studies conducted in high burden 362 settings where prevalence rates decreased over time [7, 24, 25]. In Kampala, Uganda, two community active case-363 finding campaigns that were conducted 2 years apart, the first of which occurred in 2019 prior to the pandemic, 364 365 found that TB prevalence decreased 45%. While the Ugandan surveys straddled the pandemic, similar to our 366 study, there were several key differences from our study including shorter survey intervals, sputum collection from all participants regardless of symptoms, and a community mobilization component. In addition, individual 367 participation in both the Ugandan surveys was higher (33%–37%) than in our Nairobi survey (13%). These 368 369 differences raise questions around the most effective time intervals for active case-finding, the durability of reductions in TB prevalence, and the importance of identifying persons with sub-clinical TB and unremarkable 370 371 chest x-rays.

372

There remains a high burden of undiagnosed TB in Nairobi and cost-effective active case-finding strategies are needed. Among survey participants diagnosed with bacteriologically confirmed TB, 40% did not report a cough and 38% denied all of the WHO screening symptoms. In our study, chest x-ray demonstrated higher sensitivity as 88% of participants with confirmed TB had an abnormal chest X-ray suggestive of TB. This finding, in agreement with results from other prevalence surveys [3, 26], emphasizes the importance of chest imaging for detecting persons with prevalent TB in the community [27, 28].

379

Development of cost-effective TB case-finding strategies will need to account for behavioral patterns and local 380 variations in epidemiology. Through door-to-door enrollment, our 2022 TB prevalence survey enrolled twice as 381 many women as men, similar frequencies to other surveys [10], yet weighted TB prevalence was three times 382 higher among men than women, again similar to other surveys [24, 29]. This suggests that active case-finding 383 approaches will need to identify strategies to increase inclusion of men such as enrollment through non-384 household locales or performing screening outside of business hours. Further studies of activity spaces and TB 385 risk may help to inform this work. By age group, we verified 2015 findings that older age groups, especially 45-54 386 387 years, in Nairobi clusters have the highest TB prevalence which differs from aggregated country-wide data in Kenya (highest prevalence among 25-34 year-olds), and national data from 11 other African nations [10]. Stability 388 of this risk factor among Nairobi clusters supports the development of interventions specific to Nairobi clusters. 389 390 Intentionally performing active case-finding among 45-64 year-old men in Nairobi County is one strategy to maximize the detection of TB. 391

392

Based on our study definition of TB, sensitivity of Xpert Ultra performed on a single sputum sample (88%) was no 393 394 different than that of MGIT culture performed on two specimens (76%). Relying solely on Xpert Ultra in our study would have missed 5 of the 42 persons (12%) with confirmed with TB. The sensitivity of a single Xpert Ultra test 395 396 to that of a single MGIT culture is similar [30], and it has been suggested that primary use of Xpert Ultra with culture for confirmatory testing in prevalence surveys may be a cost-effective approach [17]. We observed that 397 Ultra trace-positive/culture-negative results were identified in 2% of participants who submitted sputum. Other 398 community-based surveys found that of participants who submitted sputum, 0.4% to 2% had Xpert Ultra trace 399 positive results and that 14% to 43% of the trace positive samples were positive using one to two specimens for 400 culture [14, 30, 31]. Different from these findings, under our study protocol we did not detect any culture positive 401 samples from participants with Xpert Ultra trace-positive results (n=31). Seventeen of these 31 participants 402 enrolled in a study of TB infectiousness [18] and provided spot and morning sputum samples: all were trace 403 positive on Xpert Ultra retesting and four (24%) were culture positive on one of two specimens. Based on these 404 405 findings we suggest that trace positive results be investigated with high quality sputum collection that is submitted for culture, and that multiple sputa submitted for culture is important in confirming culture status. 406 407 Most persons with trace positive Xpert Ultra sputum who are tested through active case-finding will be culture 408 negative with an unknown role for TB treatment.

409

There are a number of limitations in our study. While the 2015 survey was powered to sample clusters across 410 Kenya in order to provide an estimate of country-wide prevalence, our 2022 survey targeted only clusters located 411 within Nairobi County. Our findings pertain to geographic clusters that are relatively stable in terms of residency 412 413 as 63% of participants reported living in the same cluster in 2015. Our study enrolled participants in the wake of the COVID pandemic and it is unclear how this impacted TB prevalence in the surveyed clusters. 414

415

The Nairobi 2022 prevalence survey presents a major strength by returning to previously sampled areas to 416 examine the evolution of TB prevalence over time. As a repeat survey of TB prevalence it allows for assessing 417 trends in TB prevalence within a time interval of at least five years for Nairobi County. Comparing TB prevalence 418 across time allows public health authorities to examine the trend in burden, evaluate the impact of TB control 419 activities between surveys, and create policies to direct future actions. Another unique aspect of this survey was 420 that it was conducted in the backdrop of the COVID-19 pandemic and aimed to provide useful insights on TB care 421 in the setting of a pandemic. This information would be crucial for programmatic management. 422

423

Acknowledgements 424

We acknowledge the study field team that collected the study data, the Kenya National TB Program and the Nairobi 425 county health mangement team for facilitating the conduction of this study 426

427

References 428

429 1. World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization; 2023. 430 Licence: CC BY-NC-SA 3.0 IGO.

Pai M, Dewan PK, Swaminathan S. Transforming tuberculosis diagnosis. Nat Microbiol. 2023;8(5):756-9. 431 2.

432 3. Enos M, Sitienei J, Ong'ang'o J, Mungai B, Kamene M, Wambugu J, et al. Kenya tuberculosis prevalence survey 2016: Challenges and opportunities of ending TB in Kenya. PLoS ONE. 2018;13(12):e0209098. 433

NTLD. Kenya tuberculosis prevalence survey 2016. Nairobi, Kenya: National Tuberculosis, Leprosy and Lung 434 4. 435 Disease Program, 2018. Accessed at: https://nltp.co.ke/wp-content/uploads/2020/10/Kenya-TB-Prevalence-Survey-436 Report-March-2018.pdf.

437 World Health Organization. Tuberculosis prevalence surveys: a handbook. Geneva: World Health 5. 438 Organization; 2011.

439 Frascella B, Richards AS, Sossen B, Emery JC, Odone A, Law I, et al. Subclinical Tuberculosis Disease-A Review 6. 440 and Analysis of Prevalence Surveys to Inform Definitions, Burden, Associations, and Screening Methodology. Clin 441 Infect Dis. 2021;73(3):e830-e41.

442 Nguyen HV, Nguyen HB, Nguyen NV, Cobelens F, Finlay A, Dao CH, et al. Decline of Tuberculosis Burden in 7. Vietnam Measured by Consecutive National Surveys, 2007-2017. Emerg Infect Dis. 2021;27(3):872-9. 443

444 8. Aung ST, Nyunt WW, Moe MM, Aung HL, Lwin T. The fourth national tuberculosis prevalence survey in 445 Myanmar. PLOS Glob Public Health. 2022;2(6):e0000588.

446 9. Lansang MAD, Alejandria MM, Law I, Juban NR, Amarillo MLE, Sison OT, et al. High TB burden and low 447 notification rates in the Philippines: The 2016 national TB prevalence survey. PLoS ONE. 2021;16(6):e0252240. 448 Law I, Floyd K, African TBPSG. National tuberculosis prevalence surveys in Africa, 2008-2016: an overview of 10. 449 results and lessons learned. Trop Med Int Health. 2020;25(11):1308-27.

450 National Tuberculosis, Leprosy and Lung Disease Program Annual Report, 2021; Ministry of Health, Kenya. 11.

451 12. Van't Hoog A, Viney K, Biermann O, Yang B, Leeflang MM, Langendam MW. Symptom- and chestradiography screening for active pulmonary tuberculosis in HIV-negative adults and adults with unknown HIV status. 452 Cochrane Database Syst Rev. 2022;3(3):CD010890. 453

Cruciani M, Scarparo C, Malena M, Bosco O, Serpelloni G, Mengoli C. Meta-analysis of BACTEC MGIT 960 and 454 13. 455 BACTEC 460 TB, with or without solid media, for detection of mycobacteria. J Clin Microbiol. 2004;42(5):2321-5. 456 14. Moyo S, Ismail F, Van der Walt M, Ismail N, Mkhondo N, Dlamini S, et al. Prevalence of bacteriologically

confirmed pulmonary tuberculosis in South Africa, 2017-19: a multistage, cluster-based, cross-sectional survey. 457 458 Lancet Infect Dis. 2022;22(8):1172-80.

Sung J, Nantale M, Nalutaaya A, Biche P, Mukiibi J, Kamoga CE, et al. Evidence for tuberculosis in individuals 459 15. 460 with Xpert Ultra "trace" sputum during screening of high-burden communities. Clin Infect Dis. 2023.

461 16. Zifodya JS, Kreniske JS, Schiller I, Kohli M, Dendukuri N, Schumacher SG, et al. Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis. 462 463 Cochrane Database Syst Rev. 2021;2:CD009593.

464 Floyd S, Klinkenberg E, de Haas P, Kosloff B, Gachie T, Dodd PJ, et al. Optimising Xpert-Ultra and culture 17. testing to reliably measure tuberculosis prevalence in the community: findings from surveys in Zambia and South 465 466 Africa. BMJ Open. 2022;12(6):e058195.

467 18. Nduba V, Njagi L, Murithi W, Mwongera Z, Byers J, Logioia G, et al. Mycobacterium tuberculosis Cough 468 Aerosol Culture Status Associates with Host Characteristics and Inflammatory Profiles. Nat Comms. 2024. 469 Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a 19. 470 metadata-driven methodology and workflow process for providing translational research informatics support. J 471 Biomed Inform. 2009;42(2):377-81.

World Health Organization. Assessing tuberculosis under-reporting through inventory studies. WHO Press. 472 20. 473 2012. https://www.who.int/tb/publications/inventory_studies/en/. 474 21. National Tuberculosis, Leprosy and Lung Disease Program Annual Report, 2022; Ministry of Health, Kenya. 22. Kiarie H, Temmerman M, Nyamai M, Liku N, Thuo W, Oramisi V, et al. The COVID-19 pandemic and 475 476 disruptions to essential health services in Kenya: a retrospective time-series analysis. Lancet Glob Health. 477 2022;10(9):e1257-e67. 478 23. Foster N, Nguyen HV, Nguyen NV, Nguyen HB, Tiemersma EW, Cobelens FGJ, et al. Social determinants of 479 the changing tuberculosis prevalence in Viet Nam: Analysis of population-level cross-sectional studies. PLoS Med. 2022;19(3):e1003935. 480 481 24. Feasey HRA, Khundi M, Nzawa Soko R, Nightingale E, Burke RM, Henrion MYR, et al. Prevalence of 482 bacteriologically-confirmed pulmonary tuberculosis in urban Blantyre, Malawi 2019-20: Substantial decline compared to 2013-14 national survey. PLOS Glob Public Health. 2023;3(10):e0001911. 483 484 25. Kendall EA, Kitonsa PJ, Nalutaaya A, Robsky KO, Erisa KC, Mukiibi J, et al. Decline in prevalence of tuberculosis following an intensive case finding campaign and the COVID-19 pandemic in an urban Ugandan 485 486 community. Thorax. 2024;79(4):325-31. 487 Nguyen HV, Tiemersma EW, Nguyen HB, Cobelens FGJ, Finlay A, Glaziou P, et al. The second national 26. tuberculosis prevalence survey in Vietnam. PLoS ONE. 2020;15(4):e0232142. 488 489 27. Ho J, Fox GJ, Marais BJ. Passive case finding for tuberculosis is not enough. Int J Mycobacteriol. 490 2016;5(4):374-8. 491 28. Kuznetsov VN, Grjibovski AM, Mariandyshev AO, Johansson E, Bjune GA. A comparison between passive and 492 active case finding in TB control in the Arkhangelsk region. Int J Circumpolar Health. 2014;73:23515. 493 Horton KC, MacPherson P, Houben RM, White RG, Corbett EL. Sex Differences in Tuberculosis Burden and 29. Notifications in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis. PLoS Med. 494 495 2016;13(9):e1002119. 496 30. Xie YL, Eichberg C, Hapeela N, Nakabugo E, Anyango I, Arora K, et al. Xpert MTB/RIF Ultra versus 497 mycobacterial growth indicator tube liquid culture for detection of Mycobacterium tuberculosis in symptomatic 498 adults: a diagnostic accuracy study. Lancet Microbe. 2024;5(6):e520-e8. 499 Sung J, Nantale M, Nalutaaya A, Biche P, Mukiibi J, Kamoga CE, et al. Evidence for Tuberculosis in Individuals 31. With Xpert Ultra "Trace" Sputum During Screening of High-Burden Communities. Clin Infect Dis. 2024;78(3):723-9. 500 501 502 503 504 505 506 507 508 509